Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Sales | 7,320,000 | 7,384,000 | 7,586,000 | 7,542,000 | 6,532,000 |
| Cost of Goods | 2,619,000 | 2,513,000 | 2,508,000 | 2,525,000 | 2,124,000 |
| Gross Profit | 4,701,000 | 4,871,000 | 5,078,000 | 5,017,000 | 4,408,000 |
| Operating Expenses | 4,721,000 | 3,153,000 | 1,055,000 | 3,586,000 | 4,559,000 |
| Operating Income | -20,000 | 1,718,000 | 4,023,000 | 1,431,000 | -151,000 |
| Interest Expense | 192,000 | 194,000 | 174,000 | 179,000 | 183,000 |
| Other Income | 34,000 | 26,000 | -3,426,000 | 22,000 | 16,000 |
| Pre-tax Income | -178,000 | 1,550,000 | 423,000 | 1,274,000 | -318,000 |
| Income Tax | -92,000 | 327,000 | 106,000 | 389,000 | 174,000 |
| Net Income Continuous | -86,000 | 1,223,000 | 317,000 | 885,000 | -492,000 |
| Minority Interests | -94,000 | -177,000 | -60,000 | -77,000 | 57,000 |
| Net Income | $-180,000 | $1,046,000 | $257,000 | $808,000 | $-435,000 |
| EPS Basic Total Ops | -0.05 | 0.27 | 0.07 | 0.21 | -0.11 |
| EPS Basic Continuous Ops | -0.05 | 0.27 | 0.07 | 0.21 | -0.11 |
| EPS Diluted Total Ops | -0.05 | 0.27 | 0.07 | 0.21 | -0.11 |
| EPS Diluted Continuous Ops | -0.05 | 0.27 | 0.07 | 0.21 | -0.11 |
| EBITDA(a) | $1,101,000 | $2,070,000 | $1,221,000 | $1,644,000 | $266,000 |